Santen Pharmaceutical Co. Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: December 1, 2016
Pages: 50
Price:
US$ 499.00
Santen Pharmaceutical Co. Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)
ID: SB977B9C64DBEN
Leaflet:

Download PDF Leaflet

Santen Pharmaceutical Co. Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Santen Pharmaceutical Co. Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Santen Pharmaceutical Co. Ltd. and its competitors. This provides our Clients with a clear understanding of Santen Pharmaceutical Co. Ltd. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Santen Pharmaceutical Co. Ltd. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Santen Pharmaceutical Co. Ltd.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Santen Pharmaceutical Co. Ltd. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Santen Pharmaceutical Co. Ltd. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Santen Pharmaceutical Co. Ltd. business.

About Santen Pharmaceutical Co. Ltd.

Santen Pharmaceutical Co., Ltd. engages in the research, development, production and sale of prescription and over-the-counter pharmaceuticals. The company specializes in original ophthalmic and anti-rheumatic pharmaceuticals as it works to create pharmaceuticals for all types of ophthalmic disorders and offer information that meets clinical needs.

The company’s integrated operations extend from research and development to production and sales of prescription and over-the-counter pharmaceuticals.

Segments

The company operates in three segments that include Prescription Pharmaceuticals, Over-the-Counter (OTC) Pharmaceuticals, and Medical Devices.

Prescription Pharmaceuticals segment

Prescription Ophthalmics

The company holds the Japanese market for prescription ophthalmics with a share of nearly 40%. It offers treatments for a range of ophthalmic disorders and covers ophthalmologists nationwide. It also has overseas bases in the United States, Europe and Asian countries for the development, production and sale of ophthalmic pharmaceuticals.

Anti-rheumatic Pharmaceuticals

The company’s main business area is anti-rheumatic pharmaceuticals, and it provides two disease modifying anti-rheumatic drugs (DMARDs) to healthcare institutions throughout Japan for the treatment of rheumatoid arthritis. The company is in the process of strengthening its research and development efforts to develop new anti-rheumatic drugs to succeed these two products.

Over-the-Counter (OTC) Pharmaceuticals segment

The company engages in the development, production and marketing of OTC ophthalmic products, with a focus on basic treatment and eye disease prevention. Its main OTC products include Sante FX Neo, the Sante de u series and the Sante 40 series.

Medical Devices segment

The company participates in the ophthalmic devices market as a professional in the field of ophthalmology, and the ability to provide products and services to medical institutions in addition to pharmaceuticals. The company’s main products include phacoemulsification machines for cataract surgery, intraocular lenses and surgical instruments. In November 2001, the company strengthened its ability to develop intraocular lenses by acquiring the U.S. company Advanced Vision Science, Inc., which is involved in the research, development, production and marketing of intraocular lenses.

Significant Events

The company and MacuSight, Inc. have entered into a research and development collaboration and license agreement for the Japanese and Asian development and commercialization of sirolimus for the treatment of ocular diseases and conditions, including wet age related macular degeneration (wet AMD) and diabetic macular edema (DME).

History

Santen Pharmaceutical Co., Ltd. was founded in the year 1890.


The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

RESEARCH METHODOLOGY

DISCLAIMER

1. SANTEN PHARMACEUTICAL CO. LTD. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. SANTEN PHARMACEUTICAL CO. LTD. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. SANTEN PHARMACEUTICAL CO. LTD. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. SANTEN PHARMACEUTICAL CO. LTD. FINANCIAL ANALYSIS

4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. SANTEN PHARMACEUTICAL CO. LTD. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Santen Pharmaceutical Co. Ltd. Direct Competitors
5.2. Comparison of Santen Pharmaceutical Co. Ltd. and Direct Competitors Financial Ratios
5.3. Comparison of Santen Pharmaceutical Co. Ltd. and Direct Competitors Stock Charts
5.4. Santen Pharmaceutical Co. Ltd. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Santen Pharmaceutical Co. Ltd. Industry Position Analysis

6. SANTEN PHARMACEUTICAL CO. LTD. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. SANTEN PHARMACEUTICAL CO. LTD. EXPERTS REVIEW1

7.1. Experts Opinion
7.2. Experts Estimates

8. SANTEN PHARMACEUTICAL CO. LTD. ENHANCED SWOT ANALYSIS2

9. JAPAN PESTEL ANALYSIS2

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. SANTEN PHARMACEUTICAL CO. LTD. IFE, EFE, IE MATRICES2

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. SANTEN PHARMACEUTICAL CO. LTD. PORTER FIVE FORCES ANALYSIS2

12. SANTEN PHARMACEUTICAL CO. LTD. VRIO ANALYSIS2


APPENDIX: RATIO DEFINITIONS


LIST OF TABLES

Santen Pharmaceutical Co. Ltd. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Santen Pharmaceutical Co. Ltd. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Santen Pharmaceutical Co. Ltd. Major Shareholders
Santen Pharmaceutical Co. Ltd. History
Santen Pharmaceutical Co. Ltd. Products
Revenues by Segment
Revenues by Region
Santen Pharmaceutical Co. Ltd. Offices and Representations
Santen Pharmaceutical Co. Ltd. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Santen Pharmaceutical Co. Ltd. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Santen Pharmaceutical Co. Ltd. Capital Market Snapshot
Santen Pharmaceutical Co. Ltd. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Santen Pharmaceutical Co. Ltd. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Santen Pharmaceutical Co. Ltd. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1

LIST OF FIGURES

Santen Pharmaceutical Co. Ltd. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Santen Pharmaceutical Co. Ltd. 1-year Stock Charts
Santen Pharmaceutical Co. Ltd. 5-year Stock Charts
Santen Pharmaceutical Co. Ltd. vs. Main Indexes 1-year Stock Chart
Santen Pharmaceutical Co. Ltd. vs. Direct Competitors 1-year Stock Charts
Santen Pharmaceutical Co. Ltd. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.


PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.


Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top


Ask Your Question

Santen Pharmaceutical Co. Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: